Tirzepatide (the active ingredient in Mounjaro and Zepbound) is one of the most effective medications available for weight management and type 2 diabetes, and with that attention has come a lot of misinformation. Below we separate fact from fiction on the questions patients ask most, with the evidence behind each answer.
Myth 1: "Tirzepatide causes rapid, dramatic weight loss overnight"
Fact: Weight loss with tirzepatide is significant but gradual. In the SURMOUNT-1 trial, adults with obesity or overweight lost an average of 20.9% of their body weight on the 15 mg dose, but that result came over 72 weeks of treatment paired with lifestyle changes.[1] It is a steady, months-long process, not an overnight change, and it works best as part of a longer-term plan for your health.
Myth 2: "It's just a lazy person's quick fix"
Fact: Tirzepatide is a medical treatment for a medical condition, not a shortcut. It reduces appetite and food noise so that changes to diet and activity become sustainable, but the medication and healthy habits work together. Research consistently shows that weight loss is better maintained when medication is paired with ongoing nutrition and physical-activity support.
Myth 3: "It works the same for everyone"
Fact: Individual responses vary. Starting weight, body composition, other health conditions, diet, and activity level all influence how much weight a person loses and how well they tolerate the medication. This is exactly why tirzepatide should be prescribed and monitored by a licensed clinician who can adjust your dose over time.
Myth 4: "Tirzepatide is an anabolic steroid"
Fact: No. Tirzepatide is not a steroid. It is a peptide that activates two gut-hormone receptors, GLP-1 and GIP, to regulate appetite, blood sugar, and how your body processes food.[1] Anabolic steroids are synthetic derivatives of testosterone and act through completely different pathways. The two have nothing in common beyond both being prescription medications.
Myth 5: "Tirzepatide doesn't affect birth control"
Fact: This one is important to get right. Tirzepatide can reduce the effectiveness of oral hormonal contraceptives (the pill). It does not do this by changing your hormones; it slows stomach emptying, which can lower how much of the pill your body absorbs, an effect that is strongest after your first dose and after each dose increase. The Mounjaro prescribing information advises people using oral contraceptives to switch to a non-oral method or add a barrier method, such as condoms, for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase.[3] Non-oral methods, including IUDs, implants, injections, patches, and vaginal rings, are not affected. Always tell your clinician what contraception you use.
Myth 6: "You'll be miserable and nauseous 24/7"
Fact: Gastrointestinal side effects are the most common ones, but they are usually mild to moderate and tend to ease as your body adjusts. In SURMOUNT-1, nausea affected about 31% of people on the 15 mg dose, and most stayed on treatment; only about 6% stopped because of side effects.[1] Symptoms are most noticeable during dose escalation, which is one reason clinicians start low and increase the dose slowly.
Myth 7: "Tirzepatide makes you lose muscle"
Fact: Any substantial weight loss, from any method, includes some loss of lean mass along with fat. This is not unique to tirzepatide. You can protect muscle by eating enough protein and doing regular resistance training while you lose weight. The goal of treatment is to reduce excess fat, and that can be done while preserving strength.
How tirzepatide compares to semaglutide
Tirzepatide and semaglutide are often compared. In SURMOUNT-5, the first head-to-head trial of the two, adults with obesity lost an average of 20.2% of their body weight on tirzepatide versus 13.7% on semaglutide over 72 weeks.[4] That is consistent with each drug's individual pivotal trials (about 20.9% for tirzepatide in SURMOUNT-1 and about 14.9% for semaglutide in STEP-1).[1][2] Both are highly effective, and the better choice depends on the individual. If you are deciding between the two, see our guide on semaglutide vs. tirzepatide.
The bottom line
Tirzepatide is a well-studied, effective medication, but it is still a prescription medication that deserves accurate information and clinical oversight. The most important step is a conversation with a licensed clinician who can review your history, set the right dose, and monitor your progress. At IVUSE+, compounded tirzepatide is prescribed and managed through async telehealth by licensed clinicians. You can learn more about compounded tirzepatide or review the full tirzepatide safety information before starting.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine. 2021;384:989-1002.
- Mounjaro (tirzepatide) Prescribing Information, Eli Lilly and Company: Drug Interactions, Oral Hormonal Contraceptives.
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. 2025;392:2225-2237.
This article is for general education and is not medical advice. Compounded medications are not FDA-approved. Talk with a licensed clinician about whether tirzepatide is appropriate for you.
